카이노스메드
1,087KRWMarket close of 10/20 (Tue)
No trade that dayMarket close of 10/20 (Tue)
Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/21 (Wed)1,087KRWFlat 0.00%
Preliminary · just after the close · replaced by official KRX data tomorrow morning
- Volume
- 0×10K shares
- 0 KRW
Open, high and low are not shown — the source has no bar for the reference date
Market close of 10/20 (Tue)
Where it sits in the 1-year range
2%2% of the way up from the lowest close in 1 year (252 sessions) · -80.4% from the high
Something to check
2 to check: no trades this day · operating loss
Free · no sign-inSource from 2021-05-17
Points to check
- Daily moveto checkNo trades this day (0 shares)
- Earningsto check-5.8B KRWOperating income over the last four quarters -5.8B KRW (loss)
- Trading valuenot verifiedNo trading that day, so not compared with usual trading value
The other 3
- Recent filingsnot verified
- Foreign & institutionalnot verified
- Data date10/20 (Tue)Market close
See the full check report
Quarterly results · Q1 2026
- Revenue370.34 million KRW
- vs. year ago
- +0.4%
- vs. prior quarter
- +21.8%
- Operating income-1.0B KRW
- vs. year ago
- Still a loss
- vs. prior quarter
- Still a loss
- Operating margin-273.2%
- vs. year ago
- +184.9 pp
- vs. prior quarter
- +482.6 pp
Quarterly operating income trend
As of the latest official close · 2026-10-20Valuation filing date · 2026-05-15Same sector · 바이오 R&D
Down -2.19%· 16 of 64 stocks up, preferred shares excluded · trading value 190.5B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -9.6% | Down -3.35% | 51.1B KRW |
| 올릭스 | Close over the last 20 sessions -12.2% | Down -4.03% | 19.1B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -11.8% | Down -1.93% | 15.1B KRW |
| 리가켐바이오 | Close over the last 20 sessions -15.4% | Down -1.41% | 12.1B KRW |
| 프로티나 | Close over the last 20 sessions +31.8% | Up +7.38% | 10.0B KRW |
Schedule
- Next data 10/22 (Thu) after 08:50
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 81% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.